918 related articles for article (PubMed ID: 18083404)
1. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
; Gray R; Barnwell J; McConkey C; Hills RK; Williams NS; Kerr DJ
Lancet; 2007 Dec; 370(9604):2020-9. PubMed ID: 18083404
[TBL] [Abstract][Full Text] [Related]
2. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group.
Lancet; 2000 May; 355(9215):1588-96. PubMed ID: 10821362
[TBL] [Abstract][Full Text] [Related]
3. A United Kingdom coordinating committee on cancer research study of adjuvant chemotherapy for colorectal cancer: preliminary results.
Kerr DJ
Semin Oncol; 2001 Feb; 28(1 Suppl 1):31-4. PubMed ID: 11273587
[TBL] [Abstract][Full Text] [Related]
4. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
[TBL] [Abstract][Full Text] [Related]
5. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
Scheithauer W; Kornek GV; Marczell A; Karner J; Salem G; Greiner R; Burger D; Stöger F; Ritschel J; Kovats E; Vischer HM; Schneeweiss B; Depisch D
Br J Cancer; 1998 Apr; 77(8):1349-54. PubMed ID: 9579845
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group.
Kerr DJ; Gray R; McConkey C; Barnwell J
Ann Oncol; 2000 Aug; 11(8):947-55. PubMed ID: 11038030
[TBL] [Abstract][Full Text] [Related]
7. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.
Punt CJ; Nagy A; Douillard JY; Figer A; Skovsgaard T; Monson J; Barone C; Fountzilas G; Riess H; Moylan E; Jones D; Dethling J; Colman J; Coward L; MacGregor S
Lancet; 2002 Aug; 360(9334):671-7. PubMed ID: 12241873
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
Nordlinger B; Rougier P; Arnaud JP; Debois M; Wils J; Ollier JC; Grobost O; Lasser P; Wals J; Lacourt J; Seitz JF; Guimares dos Santos J; Bleiberg H; Mackiewickz R; Conroy T; Bouché O; Morin T; Baila L; van Cutsem E; Bedenne L
Lancet Oncol; 2005 Jul; 6(7):459-68. PubMed ID: 15992694
[TBL] [Abstract][Full Text] [Related]
9. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
10. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.
Porschen R; Bermann A; Löffler T; Haack G; Rettig K; Anger Y; Strohmeyer G;
J Clin Oncol; 2001 Mar; 19(6):1787-94. PubMed ID: 11251010
[TBL] [Abstract][Full Text] [Related]
11. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial.
Kerr DJ; McArdle CS; Ledermann J; Taylor I; Sherlock DJ; Schlag PM; Buckels J; Mayer D; Cain D; Stephens RJ; ;
Lancet; 2003 Feb; 361(9355):368-73. PubMed ID: 12573372
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1).
Baumgaertner I; Quinaux E; Khalil A; Louvet C; Buyse M; de Gramont A; André T;
Clin Colorectal Cancer; 2010 Apr; 9(2):E5-10. PubMed ID: 20378497
[TBL] [Abstract][Full Text] [Related]
13. The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group.
Bleeker WA; Mulder NH; Hermans J; Otter R; Plukker JT
Ann Oncol; 2000 May; 11(5):547-52. PubMed ID: 10907947
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1.
Staib L; Link KH; Beger HG;
J Gastrointest Surg; 2001; 5(3):275-81. PubMed ID: 11419451
[TBL] [Abstract][Full Text] [Related]
15. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.
Comella P; Massidda B; Natale D; Putzu C; Sandomenico C; Filippelli G; Palmeri S; Condemi G; Vessia G; Barberis G; Ionta MT; Tafuto S; Barbato E
Clin Colorectal Cancer; 2011 Mar; 10(1):42-7. PubMed ID: 21609935
[TBL] [Abstract][Full Text] [Related]
18. [Cytoreductive surgery as an alternative to palliative operations in oncology (the model of treatment of stage IV colorectal cancer)].
Grinev MV
Vestn Khir Im I I Grek; 2002; 161(6):100-3. PubMed ID: 12638509
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
20. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.
O'Connell MJ; Mailliard JA; Kahn MJ; Macdonald JS; Haller DG; Mayer RJ; Wieand HS
J Clin Oncol; 1997 Jan; 15(1):246-50. PubMed ID: 8996149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
